COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety
Patients with cancer have a higher risk of severe coronavirus disease (COVID-19) and
associated mortality than the general population. Owing to this increased risk, patients with …
associated mortality than the general population. Owing to this increased risk, patients with …
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
In the post-pandemic COVID-19 period, human activities have returned to normal and
COVID-19 cases are usually mild. However, patients with multiple myeloma (MM) present an …
COVID-19 cases are usually mild. However, patients with multiple myeloma (MM) present an …
Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies
Despite therapeutic advances against SARS-CoV-2, including multiple vaccines, oral
antiviral therapies, and monoclonal antibodies, patients with hematologic malignancies …
antiviral therapies, and monoclonal antibodies, patients with hematologic malignancies …
Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis
N Gagelmann, F Passamonti, C Wolschke… - …, 2021 - pmc.ncbi.nlm.nih.gov
Vaccines against SARS-CoV-2 have shown remarkable efficacy and thus constitute an
important preventive option against coronavirus disease 2019 (COVID-19), especially in …
important preventive option against coronavirus disease 2019 (COVID-19), especially in …
[HTML][HTML] Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges
E Amanatidou, A Gkiouliava, E Pella, M Serafidi… - Metabolism open, 2022 - Elsevier
Vaccination programs against SARS-CoV-2 constitute the mainstay of public health
interventions against the global COVID-19 pandemic. Currently available vaccines have …
interventions against the global COVID-19 pandemic. Currently available vaccines have …
Determinants of neutralizing antibody response after SARS CoV-2 vaccination in patients with myeloma
AK Nooka, U Shanmugasundaram… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE Vaccine-induced neutralizing antibodies (nAbs) play a critical role in protection
from SARS CoV-2. Patients with B-cell malignancies including myeloma are at increased …
from SARS CoV-2. Patients with B-cell malignancies including myeloma are at increased …
Seroconversion and outcomes after initial and booster COVID‐19 vaccination in adults with hematologic malignancies
Background Patients with hematologic malignancies have impaired humoral immunity
secondary to their malignancy and its treatment, placing them at risk of severe coronavirus …
secondary to their malignancy and its treatment, placing them at risk of severe coronavirus …
CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished Immunity
To obtain a deeper understanding of poor responses to COVID-19 vaccination in patients
with lymphoma, we assessed blocking antibodies, total anti-spike IgG, and spike-specific …
with lymphoma, we assessed blocking antibodies, total anti-spike IgG, and spike-specific …
Learning through a pandemic: the current state of knowledge on COVID-19 and cancer
The ongoing coronavirus disease 2019 (COVID-19) pandemic has left patients with current
or past history of cancer facing disparate consequences at every stage of the cancer …
or past history of cancer facing disparate consequences at every stage of the cancer …
COVID-19 vaccines, effectiveness, and immune responses
The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), has captivated the globe's attention since its emergence in 2019. This highly …
(SARS-CoV-2), has captivated the globe's attention since its emergence in 2019. This highly …